Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Cash & Current Investments (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Cash & Current Investments for 5 consecutive years, with $183.8 million as the latest value for Q1 2026.

  • For Q1 2026, Cash & Current Investments fell 14.6% year-over-year to $183.8 million; the TTM value through Mar 2026 reached $183.8 million, down 14.6%, while the annual FY2025 figure was $130.0 million, 56.69% down from the prior year.
  • Cash & Current Investments hit $183.8 million in Q1 2026 for Phathom Pharmaceuticals, up from $130.0 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $384.3 million in Q4 2023 and bottomed at $130.0 million in Q4 2025.
  • Average Cash & Current Investments over 5 years is $220.1 million, with a median of $207.9 million recorded in 2022.
  • Year-over-year, Cash & Current Investments surged 149.92% in 2024 and then crashed 59.11% in 2025.
  • Phathom Pharmaceuticals' Cash & Current Investments stood at $155.9 million in 2022, then soared by 146.49% to $384.3 million in 2023, then dropped by 21.89% to $300.1 million in 2024, then crashed by 56.69% to $130.0 million in 2025, then surged by 41.39% to $183.8 million in 2026.
  • According to Business Quant data, Cash & Current Investments over the past three periods came in at $183.8 million, $130.0 million, and $138.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.